Stepan Company (SCL) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Stepan Company for the period ended March 31, 2026. Stepan produces intermediate chemicals used in cleaning, construction, and food applications across three segments: Surfactants, Polymers, and Specialty Products. The quarter was significantly impacted by the initiation of "Project Catalyst," a strategic restructuring plan involving the shutdown of the Fieldsboro, NJ site and asset decommissioning at other locations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $604.5 million | $593.3 million |
| Gross Profit | $64.9 million | $75.5 million |
| Operating Income (Loss) | $(49.6) million | $28.3 million |
| Net Income (Loss) | $(41.4) million | $19.7 million |
| Diluted EPS | $(1.81) | $0.86 |
| Operating Cash Flow | $16.9 million | $6.9 million |
| Total Debt | $651.7 million | $626.7 million |
| Cash & Equivalents | $140.8 million | $107.5 million |
Material Changes vs. Prior Period
- Restructuring Charge: The primary driver of the Q1 2026 loss was a $65.4 million pre-tax business restructuring charge related to Project Catalyst. This included $62.4 million in asset impairment charges.
- Revenue Growth: Net sales increased 2% year-over-year, driven by a favorable foreign currency translation impact of $25.3 million and higher average selling prices. However, consolidated sales volume decreased 3%.
- Segment Performance:
- Surfactants: Sales up 5% ($453.7M), but operating income fell 36% to $18.5M due to lower unit margins and volume declines in Asia (impacted by a Philippines asset divestiture).
- Polymers: Sales down 11% ($130.0M) due to lower volumes and prices, yet operating income rose 10% to $8.8M thanks to improved margins in North America.
- Specialty Products: Sales up 24% ($20.8M) driven by volume, though operating income declined 14% due to product mix and raw material costs.
- Deferred Compensation: Deferred compensation swung from $1.0 million of income in Q1 2025 to $0.6 million of expense in Q1 2026, reflecting a rise in the company's stock price.
Guidance, Outlook, and Risks
- Restructuring Outlook: Management anticipates total restructuring expenses for the full year 2026 to range between $70 million and $80 million.
- Capital Expenditures: Estimated full-year 2026 CapEx is projected to be between $105 million and $115 million.
- Subsequent Event: On April 24, 2026, the company agreed to sell a parcel of land near its Elwood, IL site for $30 million, with closing expected in the second half of 2026.
- Environmental Contingencies: The company has accrued $19.8 million for environmental and legal losses, with a possible range of $19.8 million to $46.4 million. Significant sites include Maywood (NJ), D'Imperio (NJ), and Wilmington (MA).
- Liquidity: The company maintains a $450 million credit facility with $88.6 million available as of March 31, 2026. Net debt to net debt plus equity ratio stands at 30%.
Investor Verification Checklist
- Restructuring Execution: Verify the timeline and cost savings realization of the Fieldsboro shutdown and Millsdale/Stalybridge asset decommissioning.
- Asia Volume Recovery: Monitor the impact of the Philippines divestiture and export permit delays on Surfactant volumes in the Asia region.
- Environmental Liabilities: Track developments at the Maywood and Wilmington sites, as actual remediation costs could materially exceed current accruals.
- Raw Material Costs: Assess the sustainability of gross margins given the pass-through of higher oleochemical and raw material costs.
- Debt Covenants: Confirm continued compliance with the 3.50:1.00 interest coverage and net leverage ratios, especially given the current operating loss.